| Abstrakt: |
A recent study conducted by researchers at Orebro University in Sweden compared neoadjuvant therapy (NAT) to adjuvant therapy (AT) in patients with HER2-positive breast cancer. The study analyzed data from the Swedish National Quality breast cancer register and found no statistically significant differences in distant disease-free survival, breast-cancer specific survival, or overall survival between NAT and AT. However, subgroup analyses showed that NAT may be more beneficial for patients with clinically positive lymph node status. The study suggests that NAT may have a higher possibility of improving long-term prognosis for patients with HER2-positive breast cancer. [Extracted from the article] |
